CuraScientific (CuraScientific) Change In Receivables : $0.02 Mil (TTM As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is CuraScientific Change In Receivables?

CuraScientific's change in receivables for the quarter that ended in Sep. 2023 was $0.00 Mil. It means CuraScientific's Accounts Receivable stayed the same from Jun. 2023 to Sep. 2023 .

CuraScientific's change in receivables for the fiscal year that ended in Dec. 2022 was $0.04 Mil. It means CuraScientific's Accounts Receivable declined by $0.04 Mil from Dec. 2021 to Dec. 2022 .

CuraScientific's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. CuraScientific's Days Sales Outstanding for the three months ended in Sep. 2023 was 0.79.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CuraScientific's liquidation value for the three months ended in Sep. 2023 was $-26.34 Mil.

CuraScientific Change In Receivables Historical Data

The historical data trend for CuraScientific's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific Change In Receivables Chart

CuraScientific Annual Data

Trend

Dec20

Dec21

Dec22

Change In Receivables

-0.02

0.04

CuraScientific Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Receivables	Get a 7-Day Free Trial							-	0.02	-	-	-

CuraScientific Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

CuraScientific (OTCPK:CSTF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CuraScientific's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.002	/	0.23	*	91
=	0.79

2. In Ben Graham's calculation of liquidation value, CuraScientific's accounts receivable are only considered to be worth 75% of book value:

CuraScientific's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.041	-	26.401	+	0.75 * 0.002	+	0.5 * 0.045
=	-26.34

CuraScientific Change In Receivables Related Terms

Thank you for viewing the detailed overview of CuraScientific's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

CuraScientific (CuraScientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236

Website

https://www.curascientificcorp.com

CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.

Executives

Paul Quentin Goyette	director	2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed	director, officer: Chief Executive Officer	333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen	director	C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette	director	13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez	director, officer: Chief Executive Officer	15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson	director, officer: Chief Operating Officer	19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

BOON Industries Debuts DiOx+ With $2M in Projected Revenue for Next 12 Months

By Marketwired Marketwired • 05-27-2020

BOON Industries Announces Initial Purchase Order With Major Beverage Company of 500,000 Units

By Marketwired Marketwired • 05-21-2020

Boon Industries Moves Forward With New Technology & Intellectual Property

By Marketwired Marketwired • 05-19-2020

BOON to Announce Major Contract Start Date for DIOX+ $52M Revenue Stream

By Marketwired Marketwired • 02-03-2021

Introducing Leaf of Faith

By Marketwired Marketwired • 03-26-2019